We would welcome your comments on the draft All Wales HIV-1 Antiretroviral Prescribing Guidelines and the associated Equality and Health Impact Assessment (EqHIA) form.
Antiretroviral therapy (ART) is licensed for the treatment of human immunodeficiency virus type 1 (HIV-1). The aim of ART is to suppress the viral load, reduce mortality and morbidity associated with HIV infection, reduce onwards transmission and prevent the development of acquired immune deficiency syndrome. Over the years, treatment outcomes with ART have improved significantly with respect to clinical effectiveness and tolerability.
The purpose of an All Wales HIV-1 antiretroviral prescribing guideline is to support consistency across Wales in the evidence-based and prudent prescribing of antiretroviral therapy for the treatment of HIV-1. The guidance aims to support clinicians and other healthcare professionals in the pharmacological management of HIV-1 to deliver good prescribing practice, optimise treatment to suppress the viral load while minimising the risk of adverse effects, and improve the person’s health-related quality of life.
The document and associated EqHIA form and feedback form can be accessed below.
Closing date: Friday 5th December 2025
⇩ All Wales HIV-1 Antiretroviral Prescribing Guidelines 170KB (PDF) |
⇩ All Wales HIV-1 Antiretroviral Prescribing Guidelines EqHIA 89KB (PDF) |
⇩ All Wales HIV-1 Antiretroviral Prescribing Guidelines Feedback form 37KB (.doc) |